| Literature DB >> 31245180 |
Ronghao Wan1, Lei Li1, Chenwei Xing2, Ronggang Peng3, Liang Gao1.
Abstract
BACKGROUND: Sepsis represents a significant healthcare problem worldwide and causes a high number of deaths every year but remains to be fully understood. During and after sepsis, the host immune response is complex and involves an initial excessive host inflammatory response to infection that is closely related to tissue damage and leads to organ failure. Over the past three decades, immunotherapy for sepsis has vastly improved, but in this area, the most influential articles, journals, authors, and countries have not yet been completely summarized and analyzed.Entities:
Keywords: Bibliometric analysis; Immunotherapy; Sepsis
Year: 2019 PMID: 31245180 PMCID: PMC6585897 DOI: 10.7717/peerj.7116
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1The distribution of publications about immunotherapy for sepsis on the Scopus database in each year.
Note: 1963, 1965, 1966, 1968, 1969, 1971, 1972, 1973, 1976, 1980 published the number of articles is zero, so it is not presented in the diagram.
Top 10 most-cited articles about immunotherapy of sepsis.
| Title | Publication year | Journals (citescore 2017) | First author | Country | Scopus citations |
|---|---|---|---|---|---|
| Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012 | 2013 | Critical Care Medicine (3.24) | Dellinger, Richard Phillip | US | 3,435 |
| The third international consensus definitions for sepsis and septic shock (sepsis-3) | 2016 | JAMA (7.30) | Singer, Mervyn | UK | 2,859 |
| The pathophysiology and treatment of sepsis | 2003 | New England Journal of Medicine (14.75) | Hotchkiss, Richard S. | US | 2,711 |
| Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012 | 2013 | Intensive Care Medicine (3.99) | Dellinger, Richard Phillip | US | 2,409 |
| Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial | 1994 | JAMA (7.30) | Fisher, Charles J. | US | 842 |
| Immunosuppression in patients who die of sepsis and multiple organ failure | 2011 | JAMA (7.30) | Boomer, Jonathan S. | US | 666 |
| Novel strategies for the treatment of sepsis | 2003 | Nature Medicine (16.81) | Riedemann, Niels Christoph | Germany | 635 |
| Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy | 2013 | Nature Reviews Immunology (17.43) | Hotchkiss, Richard S. | US | 593 |
| A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis | 1991 | JAMA (7.30) | Greenman, Richard L. | US | 583 |
| Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial | 1997 | Critical Care Medicine (3.24) | Opal, Steven M. | US | 553 |
The top 10 countries with publications about immunotherapy for sepsis and ranked by the publication numbers.
| Countries/Territories | Record count | % of 1,483 |
|---|---|---|
| US | 604 | 41 |
| China | 163 | 11 |
| Germany | 158 | 11 |
| UK | 100 | 7 |
| France | 81 | 5 |
| Netherlands | 69 | 5 |
| Canada | 47 | 3 |
| Italy | 40 | 3 |
| Australia | 39 | 3 |
| Japan | 39 | 3 |
The data of 62 different countries with publications and ranked by GDP (current US $) in 2017.
| Countries | GDP (million $) |
|---|---|
| US | 19,390,604 |
| China | 12,237,700 |
| Japan | 4,872,137 |
| Germany | 3,677,439 |
| UK | 3,622,434 |
| India | 2,597,491 |
| France | 2,582,501 |
| Brazil | 2,055,506 |
| Italy | 1,934,798 |
| Canada | 1,653,043 |
| Russian Federation | 1,577,524 |
| Korea, Rep. | 1,530,751 |
| Australia | 1,323,421 |
| Spain | 1,311,320 |
| Mexico | 1,149,919 |
| Indonesia | 1,015,539 |
| Turkey | 851,102 |
| Netherlands | 826,200 |
| Saudi Arabia | 683,827 |
| Switzerland | 678,887 |
| Argentina | 637,590 |
| Taiwan | 579,302 |
| Sweden | 538,040 |
| Poland | 524,510 |
| Belgium | 492,681 |
| Thailand | 455,221 |
| Iran, Islamic Rep. | 439,514 |
| Austria | 416,596 |
| Norway | 398,832 |
| United Arab Emirates | 382,575 |
| Israel | 350,851 |
| South Africa | 349,419 |
| Ireland | 333,731 |
| Denmark | 324,872 |
| Singapore | 323,907 |
| Malaysia | 314,500 |
| Philippines | 313,595 |
| Colombia | 309,191 |
| Pakistan | 304,952 |
| Chile | 277,076 |
| Finland | 251,885 |
| Egypt, Arab Rep. | 235,369 |
| Portugal | 217,571 |
| Czech Republic | 215,726 |
| Romania | 211,803 |
| New Zealand | 205,853 |
| Greece | 200,288 |
| Kazakhstan | 159,407 |
| Hungary | 139,135 |
| Ethiopia | 80,562 |
| Panama | 61,838 |
| Bulgaria | 56,832 |
| Croatia | 54,849 |
| Lithuania | 47,168 |
| Serbia | 41,432 |
| Latvia | 30,264 |
| Nepal | 24,472 |
| Cyprus | 21,652 |
| Zimbabwe | 17,846 |
| Georgia | 15,081 |
| Armenia | 11,537 |
| Cuba | 8,713 |
Notes:
We obtained the data of GDP of Taiwan from CIA “The World Factbook” rather than from World Bank.
We obtained the data of GDP of Cuba in 2015 rather than in 2017.
Top 10 journals about immunotherapy for sepsis ranked by the number of the publications.
| Journals | CiteScore 2017 | Record count | % of 1,483 |
|---|---|---|---|
| Critical Care Medicine | 3.24 | 65 | 4 |
| Shock | 2.75 | 55 | 4 |
| Critical Care | 4.53 | 35 | 2 |
| PLOS ONE | 3.01 | 30 | 2 |
| American Journal of Respiratory and Critical Care Medicine | 5.10 | 25 | 2 |
| Journal of Immunology | 4.57 | 23 | 2 |
| Intensive Care Medicine | 3.99 | 21 | 1 |
| Frontiers in Immunology | 5.62 | 20 | 1 |
| Journal of Infectious Diseases | 4.47 | 19 | 1 |
| Infection and Immunity | 3.43 | 17 | 1 |
The top 10 authors with publications about immunotherapy for sepsis and ranked by the publication numbers.
| Authors | Record count | % of 1,483 |
|---|---|---|
| Opal, S.M. | 33 | 2 |
| Hotchkiss, R.S. | 29 | 2 |
| Vincent, J.L. | 20 | 1 |
| Monneret, G. | 17 | 1 |
| Coopersmith, C.M. | 16 | 1 |
| Dunn, D.L. | 16 | 1 |
| Moldawer, L.L. | 15 | 1 |
| Shankar-Hari, M. | 15 | 1 |
| Van Der Poll, T. | 14 | 1 |
| Venet, F. | 14 | 1 |